8-K: Vaxart Announces Progress in Vaccine Programs and Urges Stockholder Approval for Reverse Stock Split

Vaxart provides an update on its vaccine programs, including the lifting of a government stop work order and progress in norovirus trials, while also emphasizing the importance of a reverse stock split to maintain its Nasdaq listing.

Summary

• Vaxart has announced recent developments in its vaccine programs and is urging stockholders to vote in favor of a reverse stock split.
• A previously issued government stop work order on the COVID-19 vaccine candidate trial was lifted on April 24, 2025, allowing the trial to continue.
• The company is in active dialogue with BARDA and preparing to enroll participants for the 10,000 participant portion of the COVID-19 Phase 2b trial.
• Enrollment of all 60 participants in the norovirus program has been completed in under two months, with topline data expected in mid-2025.
• Strategic cost reductions have been implemented to extend the cash runway into 2026.
• The company is seeking additional sources of non-dilutive funding.
• Vaxart's annual meeting will be held on May 21, 2025, and a proposal to authorize a reverse stock split will be voted on.
• The reverse stock split is intended to mitigate the risk of being delisted from Nasdaq due to the minimum bid price requirement of $1.00 per share.
• Leading independent proxy advisors, Institutional Shareholder Services and Glass Lewis, have recommended stockholders vote FOR the reverse stock split proposal.
• The board of directors will only implement the reverse stock split if necessary to maintain the Nasdaq listing.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's progress in vaccine programs and cost-cutting measures, the need for a reverse stock split raises concerns about the company's financial health and stock performance.

Positives

• The lifting of the government stop work order allows the COVID-19 vaccine candidate trial to proceed, potentially unlocking further non-dilutive government funding.
• Rapid progress in the norovirus program, with topline data expected in mid-2025, could lead to a partnership and further non-dilutive funding.
• Strategic cost reductions have extended the cash runway into 2026, providing more time to achieve key milestones.
• The company is actively seeking additional non-dilutive funding sources.

Negatives

• The need for a reverse stock split indicates concern about the company's stock price and its ability to maintain Nasdaq listing compliance.
• Stockholders may be disappointed with Vaxart's stock performance.

Risks

• Failure to obtain stockholder approval for the reverse stock split could lead to delisting from Nasdaq.
• Delisting from Nasdaq could impair Vaxart's liquidity, adversely affect the value of its securities, and hinder its ability to fund initiatives and explore strategic partnerships.
• The company's agreement with BARDA requires BARDA's approval of any press release on BARDA-funded projects, which limits Vaxart's control over the timing of disclosures.

Future Outlook

Vaxart aims to deliver on multiple potentially transformative data readouts and is aggressively seeking additional sources of non-dilutive funding.

Management Comments

• We are writing to update you on recent developments that positively impact Vaxarts ability to advance our promising vaccine candidates and highlight the importance of remaining listed on Nasdaq in order to maintain our progress.
• We would greatly appreciate your voting FOR the reverse stock split proposal to continue our momentum at this critical time.
• We continue to believe Vaxart is a compelling investment opportunity, and we are dedicated to executing on the Companys strategic plan to drive long-term value.

Industry Context

The announcement acknowledges the challenging environment within the biotech sector due to macroeconomic disruption, highlighting the importance of cost control and strategic partnerships for companies like Vaxart.

Comparison to Industry Standards

• Many biotech companies in Vaxart's stage of development face similar challenges in maintaining Nasdaq listing compliance, especially given the volatility in the market.
• Seeking non-dilutive funding through government grants (like BARDA) and strategic partnerships is a common strategy for biotech firms to advance their programs without heavily relying on equity financing.
• The need for a reverse stock split is not uncommon among companies struggling to maintain the minimum bid price, but it can be viewed negatively by investors.

Stakeholder Impact

• Stockholders are urged to vote in favor of the reverse stock split to avoid potential delisting, which could negatively impact the value of their holdings.
• Employees may have been affected by the recent workforce reductions as part of the strategic cost reductions.
• The progress in vaccine programs could benefit public health by providing new options for preventing infectious diseases.

Next Steps

• Vaxart will host a Q1 2025 earnings call on May 13, 2025.
• Vaxart will conduct a webcast of its presentation at Citizens Life Sciences Conference on May 7, 2025.
• Stockholders will vote on the reverse stock split proposal at the annual meeting on May 21, 2025.
• The company will continue to screen and enroll participants for the 10,000 participant portion of the COVID-19 Phase 2b trial, pending BARDA approval.
• Topline data from the norovirus program is expected in mid-2025.

Key Dates

Keywords

Vaxart, reverse stock split, vaccine, COVID-19, norovirus, clinical trial, Nasdaq, BARDA, funding, biotech